RxDoctor Payments Data

Amy Wyatt

Nurse Practitioner · Northport, ALNPI 1265711154

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 720 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,450in general payments, 2019–2025

Across 720 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • Pfizer$1K
  • Novo Nordisk$1K
  • AstraZeneca$986
  • Lilly USA, LLC$939
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$11,450100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,450 in reported general payments places this provider in the 95th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide126$191,214
OzempicSemaglutide115$157,535
JardianceEmpagliflozin80$114,145
EliquisApixaban48$55,762
LinzessLinaclotide19$28,435
MyrbetriqMirabegron27$28,175
TrulicityDulaglutide24$26,637
Atorvastatin Calcium412$6,707
Breo ElliptaFluticasone/Vilanterol15$5,959
Pitavastatin Calcium13$4,500
Ezetimibe82$4,013
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$3,961
Rosuvastatin Calcium209$3,733
Olmesartan Medoxomil126$3,385
Levothyroxine Sodium230$3,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$939$217,851150 claims
Novo NordiskOzempic$1,062$157,535115 claims
Boehringer IngelheimJardiance$339$114,14580 claims
PfizerEliquis$1,072$55,76248 claims
AbbVieLinzess$1,847$28,43519 claims
Astellas Pharma US IncMyrbetriq$31$28,17527 claims
GSKBreo Ellipta$1,211$5,95915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Northport

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →